Company developments, deal activity, market dynamics, manufacturing, and commercialization across biotech and pharma.
The strategic landscape of prostate cancer treatment is undergoing a massive shift as Novartis prepares for regulatory filings that could reshape targeted radiotherapy. The anticipated Pluvicto label expansion is poised…
The commercial viability of radioligand therapy is intrinsically tied to one of the most unforgiving logistical networks in the healthcare industry. Unlike traditional biologics that can be physically stockpiled in…
As of early 2026, the Radioligand Therapy Market has solidified its position as the premier growth engine in oncology investing. What began as a niche diagnostic field has rapidly transformed…
The market for biotherapeutics has experienced a massive surge in transaction activity. Driven by large pharmaceutical companies seeking to replenish oncology pipelines and mid-cap biotechs aiming to establish synergistic combinations,…
As the therapeutic architecture of targeted oncology grows exponentially more complex, the state of ADC Manufacturing reveals a massive industry pivot. Producing an antibody-drug conjugate is notoriously difficult; it requires…
The artificial intelligence landscape in biopharma during 2025 and 2026 is defined by a rapid transition from exploratory pilot programs to massive, industrialized integrations across the drug development lifecycle. The…
The executive landscape of the life sciences sector remains one of the most lucrative in the global economy. As we analyze the Highest-Paid Biopharma CEOs for 2026, it is clear…
The year 2026 marks a pivotal acceleration in the biopharma patent cliff. As multiple blockbuster therapies reach their Loss of Exclusivity (LOE), the industry faces an immediate revenue headwind concentrated…
Executive Summary: As of Q1 2026, the Pharmaceutical Patent Cliff 2026 has entered a “tectonic” phase, with industry estimates projecting that over $200 billion to $275 billion in annual sales…